Melfalan Pliva

Melphalan hydrochloride, the active ingredient in Melfalan Pliva, is an alkylating agent presented as a sterile intravenous solution for infusion use. It is employed in the treatment of certain hematologic malignancies and solid tumors, including multiple myeloma, ovarian cancer and melanoma, by targeting rapidly dividing cancer cells.

GNH USA supplies Melfalan Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, ensuring timely delivery.

Melfalan Pliva (melphalan hydrochloride) is an alkylating chemotherapy used in the management of certain hematologic and solid tumor cancers. - Multiple Myeloma: Reduces disease progression and improves survival in eligible patients. - Ovarian Cancer: Enhances response rates when combined with other chemotherapeutic agents. - Melanoma: Provides therapeutic benefit in advanced-stage disease. - Other Solid Tumors: Used as part of combination regimens for various refractory solid malignancies.

Melfalan Pliva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: Gastrointestinal upset commonly reported during treatment. - Myelosuppression: Decreased white blood cells, red cells, and platelets. - Alopecia: Temporary hair loss affecting scalp and body hair. - Fatigue: Generalized tiredness that may affect daily activities.

Serious or Rare Side Effects: - Secondary malignancies: Potential development of new cancers after prolonged exposure. - Severe infection: Due to profound immunosuppression. - Pulmonary toxicity: Interstitial pneumonitis or fibrosis in rare cases.

Prior to initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity. - Blood count monitoring: Perform complete blood counts regularly to detect myelosuppression. - Renal function assessment: Evaluate serum creatinine and adjust dosing if necessary. - Hepatic function assessment: Check liver enzymes before and during treatment. - Hypersensitivity avoidance: Discontinue if signs of allergic reaction appear. - Store at controlled room temperature: Keep in original container, protect from light and moisture.

Melphalan may interact with other agents, requiring careful management.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: Increases risk of severe bone marrow suppression. - High‑dose radiation therapy: Potentiates tissue toxicity. - Live viral vaccines: May cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: Enhanced bleeding risk; monitor coagulation parameters. - Nephrotoxic drugs: May exacerbate renal impairment; adjust dosing as needed.